Sotera Health Company

NasdaqGS:SHC Stock Report

Market Cap: US$3.8b

Sotera Health Valuation

Is SHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHC ($13.24) is trading below our estimate of fair value ($32.13)

Significantly Below Fair Value: SHC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHC?

Key metric: As SHC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SHC. This is calculated by dividing SHC's market cap by their current earnings.
What is SHC's PE Ratio?
PE Ratio53.2x
EarningsUS$70.49m
Market CapUS$3.75b

Price to Earnings Ratio vs Peers

How does SHC's PE Ratio compare to its peers?

The above table shows the PE ratio for SHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.2x
SYNH Syneos Health
62.6x33.7%US$4.5b
STVN Stevanato Group
46.9x20.0%US$5.6b
CRL Charles River Laboratories International
23x12.1%US$9.5b
BRKR Bruker
28.3x15.8%US$8.6b
SHC Sotera Health
53.2x41.0%US$3.8b

Price-To-Earnings vs Peers: SHC is expensive based on its Price-To-Earnings Ratio (53.2x) compared to the peer average (32.7x).

Price to Earnings Ratio vs Industry

How does SHC's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.3xn/aUS$325.01k
No more companies available in this PE range
SHC 53.2xIndustry Avg. 36.2xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SHC is expensive based on its Price-To-Earnings Ratio (53.2x) compared to the Global Life Sciences industry average (36.2x).

Price to Earnings Ratio vs Fair Ratio

What is SHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.2x
Fair PE Ratio35.8x

Price-To-Earnings vs Fair Ratio: SHC is expensive based on its Price-To-Earnings Ratio (53.2x) compared to the estimated Fair Price-To-Earnings Ratio (35.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SHC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$13.24
US$16.19
+22.3%
13.1%US$20.00US$13.00n/a8
Dec ’25US$13.17
US$16.86
+28.0%
12.5%US$20.00US$13.00n/a7
Nov ’25US$15.86
US$16.36
+3.1%
7.8%US$18.00US$14.00n/a7
Oct ’25US$16.27
US$16.36
+0.5%
7.8%US$18.00US$14.00n/a7
Sep ’25US$15.44
US$16.36
+5.9%
7.8%US$18.00US$14.00n/a7
Aug ’25US$13.63
US$14.79
+8.5%
12.2%US$17.00US$12.00n/a7
Jul ’25US$11.58
US$14.79
+27.7%
12.2%US$17.00US$12.00n/a7
Jun ’25US$11.18
US$14.71
+31.6%
12.4%US$17.00US$12.00n/a7
May ’25US$11.27
US$16.67
+47.9%
12.8%US$20.00US$14.00n/a6
Apr ’25US$11.70
US$17.92
+53.1%
9.2%US$20.00US$15.50n/a6
Mar ’25US$14.56
US$17.83
+22.5%
9.9%US$20.00US$15.00n/a6
Feb ’25US$15.32
US$16.83
+9.9%
10.5%US$20.00US$15.00n/a6
Jan ’25US$16.85
US$16.50
-2.1%
11.5%US$20.00US$15.00n/a6
Dec ’24US$14.00
US$16.42
+17.3%
12.0%US$20.00US$14.50US$13.176
Nov ’24US$12.87
US$19.17
+48.9%
10.2%US$21.00US$15.00US$15.866
Oct ’24US$14.98
US$20.00
+33.5%
6.5%US$22.00US$18.00US$16.276
Sep ’24US$16.00
US$20.43
+27.7%
7.8%US$23.00US$18.00US$15.447
Aug ’24US$18.84
US$19.29
+2.4%
15.4%US$24.00US$16.00US$13.637
Jul ’24US$18.84
US$19.29
+2.4%
15.4%US$24.00US$16.00US$11.587
Jun ’24US$14.19
US$18.50
+30.4%
13.1%US$23.00US$16.00US$11.186
May ’24US$16.41
US$19.50
+18.8%
12.1%US$24.00US$17.00US$11.276
Apr ’24US$17.91
US$19.67
+9.8%
12.7%US$24.00US$17.00US$11.706
Mar ’24US$17.08
US$17.83
+4.4%
30.3%US$24.00US$7.00US$14.566
Feb ’24US$18.26
US$14.50
-20.6%
51.4%US$25.00US$7.00US$15.326
Jan ’24US$8.33
US$7.00
-16.0%
11.7%US$8.00US$6.00US$16.856
Dec ’23US$8.79
US$7.00
-20.4%
11.7%US$8.00US$6.00US$14.006

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sotera Health Company is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PolarkBaird
Luke SergottBarclays
Patrick DonnellyCitigroup Inc